No black box warning on record for Risedronate Sodium

As of the latest FDA labeling reviewed, Risedronate Sodium (RISEDRONATE SODIUM) does not carry a black box warning. Standard warnings and precautions still apply — see the full Risedronate Sodium medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Products Containing Same Active Ingredient : Patients receiving Actonel should not be treated with risedronate sodium delayed-release tablets (5.1) • Upper Gastrointestinal Adverse Reactions can occur. Instruct patients to follow dosing instructions. Discontinue use if new or worsening symptoms occur (5.2) • Hypocalcemia may worsen and must be corrected prior to use (5

No black box warning on record for Risedronate Sodium

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Products Containing Same Active Ingredient : Patients receiving Actonel should not be treated with risedronate sodium delayed-release tablets (5.1) • Upper Gastrointestinal Adverse Reactions can occur. Instruct patients to follow dosing instructions. Discontinue use if new or worsening symptoms occur (5.2) • Hypocalcemia may worsen and must be corrected prior to use (5

Risedronate Sodium Black Box Warning

No black box warning on record for Risedronate Sodium

Other warnings & precautions

Risedronate Sodium Black Box Warning

No black box warning on record for Risedronate Sodium

Other warnings & precautions